Premium
The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor‐infiltrating T cells
Author(s) -
Lepletier Ailin,
Lutzky Viviana P,
Mittal Deepak,
Stannard Kimberley,
Watkins Thomas S,
Ratnatunga Champa N,
Smith Corey,
McGuire Helen M,
Kemp Roslyn A,
Mukhopadhyay Pamela,
Waddell Nicola,
Smyth Mark J,
Dougall William C,
Miles John J
Publication year - 2019
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1111/imcb.12205
Subject(s) - immune system , immune checkpoint , biology , effector , microbiology and biotechnology , cancer research , lymphocyte , t cell , immunology , immunotherapy
CD 96 has recently been shown to be a potent immune checkpoint molecule in mice, but a similar role in humans is not known. In this study, we provide a detailed map of CD 96 expression across human lymphocyte lineages, the kinetics of CD 96 regulation on T‐cell activation and co‐expression with other conventional and emerging immune checkpoint molecules. We show that CD 96 is predominantly expressed by T cells and has a unique lymphocyte expression profile. CD 96 high T cells exhibited distinct effector functions on activation. Of note, CD 96 expression was highly correlated with T‐cell markers in primary and metastatic human tumors and was elevated on antigen‐experienced T cells and tumor‐infiltrating lymphocytes. Collectively, these data demonstrate that CD 96 may be a promising immune checkpoint to enhance T‐cell function against human cancer and infectious disease.